Design Therapeutics (DSGN) Earnings
Price: $3.52
Market Cap: $199.80M
Market Cap: $199.80M
Revenue (TTM): $-
Net Income: $-49.59M
Net Income: $-49.59M
P/E Ratio: -4.02
EPS (TTM): $-0.88
EPS (TTM): $-0.88
Earnings Dates
Design Therapeutics (DSGN) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 06, 2025
- Time of Day: --
- Estimated EPS: $-0.28
Last Earnings Report
- Date: March 10, 2025
- EPS: $-0.24
- EPS Estimate: $-0.28
Design Therapeutics's next earnings report is scheduled for May 06, 2025.
In its last earnings report on March 10, 2025, Design Therapeutics reported earnings per share (EPS) of $-0.24, compared to an estimated EPS of $-0.28. The company reported revenue of $-, compared to an estimated revenue of $-.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2023 | 2024-03-19 | $-0.32 | $-0.21 |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| March 10, 2025 | $-0.24 | $-0.28 | $- | $- |
| November 07, 2024 | $-0.23 | $-0.26 | $- | $- |
| August 05, 2024 | $-0.21 | $-0.25 | $- | $- |
| May 08, 2024 | $-0.20 | $-0.28 | $- | $- |
| March 19, 2024 | $-0.21 | $-0.32 | $838.00K | $- |
| November 13, 2023 | $-0.28 | $-0.42 | $- | $- |
| August 14, 2023 | $-0.36 | $-0.41 | $- | $- |
| May 09, 2023 | $-0.35 | $-0.37 | $- | $- |
| March 14, 2023 | $-0.31 | $-0.34 | $- | $- |
| November 03, 2022 | $-0.32 | $-0.28 | $- | $- |
| August 08, 2022 | $-0.27 | $-0.25 | $- | $- |
| May 09, 2022 | $-0.24 | $-0.22 | $- | $- |
| March 10, 2022 | $-0.20 | $-0.22 | $- | $- |
| November 09, 2021 | $-0.21 | $-0.14 | $- | $- |
| August 09, 2021 | $-0.14 | $-0.18 | $- | $- |
| May 10, 2021 | $-0.31 | $-0.07 | $- | $- |
| March 25, 2021 | $-0.09 | $ | $20.00K | $- |
Annual Earnings
Annual Revenue
$-
Fiscal Year 2024Annual Net Income
$-49.59M
Fiscal Year 2024Annual EPS
$-0.88
Fiscal Year 2024Quarterly Earnings
Revenue
$-
Quarter Ending December 31, 2024Net Income
$-13.65M
Quarter Ending December 31, 2024EPS
$-0.24
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-14.20%
Year Ending December 31, 2024P/E Ratio
-7.04
Year Ending December 31, 2024Revenue Per Share
$0.00
Year Ending December 31, 2024Earnings Yield (TTM)
-24.90%
Trailing Twelve MonthsP/E Ratio (TTM)
-4.02
Trailing Twelve MonthsRevenue Per Share (TTM)
$0.00
Trailing Twelve MonthsFrequently Asked Questions
Design Therapeutics's next earnings date is scheduled for May 06, 2025. The earnings call is expected to take place --.
In its last earnings report on March 10, 2025, Design Therapeutics reported earnings per share (EPS) of $-0.24, compared to an estimated EPS of $-0.28. The company reported revenue of $-, compared to an estimated revenue of $-.
Design Therapeutics's current Price-to-Earnings (P/E) ratio is -7.04. The trailing twelve months (TTM) P/E ratio is -4.02. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Design Therapeutics reported total revenue of $- and net income of $-49.59M. This represents a net profit margin of 0.
Design Therapeutics's earnings yield is -14.20%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Design Therapeutics's return on equity (ROE) is -20.48%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Design Therapeutics's gross profit margin is 0.00%. This indicates that for every dollar of revenue, the company retains $0.00 as gross profit after accounting for the cost of goods sold.
Related Metrics
Explore detailed financial metrics and analysis for DSGN.